Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial

Amit Oza; Adrian D Cook; Jacobus Pfisterer; Andrew Embleton; Jonathan A. Ledermann; Eric Pujade-lauraine; Gunnar Kristensen; Mark S Carey; Philip Beale; Andrés Cervantes; Tjoung-Won Park-Simon; Gordon Js Rustin; F Joly; Mansoor R. Mirza; Marie Plante; Michael Quinn; Andres Poveda; Gordon C Jayson; Dan Stark; Ann Marie Swart; Laura Farrelly; Richard S Kaplan; Mahesh K.b. Parmar; Timothy J. Perren

doi:10.1016/S1470-2045(15)00086-8

Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial

Amit Oza, Adrian D Cook, Jacobus Pfisterer, Andrew Embleton, Jonathan A. Ledermann, Eric Pujade-lauraine, Gunnar Kristensen, Mark S Carey, Philip Beale, Andrés Cervantes, Tjoung-Won Park-Simon, Gordon Js Rustin, F Joly, Mansoor R. Mirza, Marie Plante, Michael Quinn, Andres Poveda, Gordon C Jayson, Dan Stark, Ann Marie SwartLaura Farrelly, Richard S Kaplan, Mahesh K.b. Parmar, Timothy J. Perren

Research output: Contribution to journal › Article › peer-review

586 Citations (Scopus)

8 Downloads (Pure)

Original language	English
Pages (from-to)	928–936
Number of pages	9
Journal	The Lancet Oncology
Volume	16
Issue number	8
Early online date	24 Jun 2015
DOIs	https://doi.org/10.1016/S1470-2045(15)00086-8
Publication status	Published - Aug 2015

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S1470-2045(15)00086-8Licence: CC BY

ICON7 OS results Lancet 2015Final published version, 406 KBLicence: CC BY

Ann Marie Swart
- A.Swartuea.acuk
- Norwich Medical School - Honorary Professorial Fellow
- Cardiovascular and Metabolic Health - Member
- Health Services and Primary Care - Member
- Norwich Clinical Trials Unit - Member
- Public Health and Health Services Research - Member
Person: Honorary, Research Group Member

Cite this

Oza, A., Cook, A. D., Pfisterer, J., Embleton, A., Ledermann, J. A., Pujade-lauraine, E., Kristensen, G., Carey, M. S., Beale, P., Cervantes, A., Park-Simon, T-W., Rustin, G. J., Joly, F., Mirza, M. R., Plante, M., Quinn, M., Poveda, A., Jayson, G. C., Stark, D., ... Perren, T. J. (2015). Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. The Lancet Oncology, 16(8), 928–936. https://doi.org/10.1016/S1470-2045(15)00086-8

Oza, Amit ; Cook, Adrian D ; Pfisterer, Jacobus ; Embleton, Andrew ; Ledermann, Jonathan A. ; Pujade-lauraine, Eric ; Kristensen, Gunnar ; Carey, Mark S ; Beale, Philip ; Cervantes, Andrés ; Park-Simon, Tjoung-Won ; Rustin, Gordon Js ; Joly, F ; Mirza, Mansoor R. ; Plante, Marie ; Quinn, Michael ; Poveda, Andres ; Jayson, Gordon C ; Stark, Dan ; Swart, Ann Marie ; Farrelly, Laura ; Kaplan, Richard S ; Parmar, Mahesh K.b. ; Perren, Timothy J. / Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. In: The Lancet Oncology. 2015 ; Vol. 16, No. 8. pp. 928–936.

@article{3baca245da7c450790eafa5761644d99,

title = "Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial",

author = "Amit Oza and Cook, {Adrian D} and Jacobus Pfisterer and Andrew Embleton and Ledermann, {Jonathan A.} and Eric Pujade-lauraine and Gunnar Kristensen and Carey, {Mark S} and Philip Beale and Andr{\'e}s Cervantes and Tjoung-Won Park-Simon and Rustin, {Gordon Js} and F Joly and Mirza, {Mansoor R.} and Marie Plante and Michael Quinn and Andres Poveda and Jayson, {Gordon C} and Dan Stark and Swart, {Ann Marie} and Laura Farrelly and Kaplan, {Richard S} and Parmar, {Mahesh K.b.} and Perren, {Timothy J.}",

year = "2015",

month = aug,

doi = "10.1016/S1470-2045(15)00086-8",

language = "English",

volume = "16",

pages = "928–936",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Lancet Publishing Group",

number = "8",

}

Oza, A, Cook, AD, Pfisterer, J, Embleton, A, Ledermann, JA, Pujade-lauraine, E, Kristensen, G, Carey, MS, Beale, P, Cervantes, A, Park-Simon, T-W, Rustin, GJ, Joly, F, Mirza, MR, Plante, M, Quinn, M, Poveda, A, Jayson, GC, Stark, D, Swart, AM, Farrelly, L, Kaplan, RS, Parmar, MKB & Perren, TJ 2015, 'Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial', The Lancet Oncology, vol. 16, no. 8, pp. 928–936. https://doi.org/10.1016/S1470-2045(15)00086-8

Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. / Oza, Amit; Cook, Adrian D; Pfisterer, Jacobus; Embleton, Andrew; Ledermann, Jonathan A.; Pujade-lauraine, Eric; Kristensen, Gunnar; Carey, Mark S; Beale, Philip; Cervantes, Andrés; Park-Simon, Tjoung-Won; Rustin, Gordon Js; Joly, F; Mirza, Mansoor R.; Plante, Marie; Quinn, Michael; Poveda, Andres; Jayson, Gordon C; Stark, Dan; Swart, Ann Marie; Farrelly, Laura; Kaplan, Richard S; Parmar, Mahesh K.b.; Perren, Timothy J.

In: The Lancet Oncology, Vol. 16, No. 8, 08.2015, p. 928–936.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial

AU - Oza, Amit

AU - Cook, Adrian D

AU - Pfisterer, Jacobus

AU - Embleton, Andrew

AU - Ledermann, Jonathan A.

AU - Pujade-lauraine, Eric

AU - Kristensen, Gunnar

AU - Carey, Mark S

AU - Beale, Philip

AU - Cervantes, Andrés

AU - Park-Simon, Tjoung-Won

AU - Rustin, Gordon Js

AU - Joly, F

AU - Mirza, Mansoor R.

AU - Plante, Marie

AU - Quinn, Michael

AU - Poveda, Andres

AU - Jayson, Gordon C

AU - Stark, Dan

AU - Swart, Ann Marie

AU - Farrelly, Laura

AU - Kaplan, Richard S

AU - Parmar, Mahesh K.b.

AU - Perren, Timothy J.

PY - 2015/8

Y1 - 2015/8

U2 - 10.1016/S1470-2045(15)00086-8

DO - 10.1016/S1470-2045(15)00086-8

M3 - Article

VL - 16

SP - 928

EP - 936

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 8

ER -

Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial

UN SDGs

Access to Document

Profiles

Ann Marie Swart

Cite this